Nanoparticle-based concretes for the restoration of historical and contemporary buildings: a new way for CO2 reduction in architecture

Greco, Enrico; Ciliberto, Enrico; Verdura, Pietro Damiano; Giudice, Elio Lo; Navarra, Giuseppe

doi:10.1007/s00339-016-0056-1

Cited by 12 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cement and concrete are complex nanocomposite materials with large production scales, commercial markets, and environmental impacts. Carbon nanotubes and silicon dioxide nanoparticles can reduce the energy input for their production, decrease the porosity and increase the strength of self-compacting high-performance concrete, reduce the leaching of calcium and increase the stability of cement in water, and enable electrical monitoring of cement behavior in critical structures such as oil wells to prevent spills . Challenges include rational design of the matrix nanostructure, economical production of a large quantity of nanoparticles, and control of their dispersion from agglomerates into liquid cements …”

Section: Commercial Applicationsmentioning

confidence: 99%

Nanoparticle Manufacturing – Heterogeneity through Processes to Products

Stavis¹,

Fagan²,

Stopa

et al. 2018

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Commercial products are now making use of the unique properties of nanoscale particles. However, common challenges of making nanoparticles into products still limit their impact. In this article, we review recent advances in nanoparticle manufacturing in liquids, clarifying the similarities between different processes and products at a system level. Our integrative survey emphasizes the fundamental challenge of heterogeneity, which propagates through manufacturing processes and increases the cost of quality control. We also consider the central constraint of production scale, external costs of safety and sustainability, and technology transfer from the laboratory to the market. We review applications of nanoparticles in nanocomposite materials, healthcare and medicine, electronics and photonics, and energy and the environment, and conclude with a summary of the critical issues.

show abstract

Section: Commercial Applicationsmentioning

confidence: 99%

Nanoparticle Manufacturing – Heterogeneity through Processes to Products

Stavis¹,

Fagan²,

Stopa

et al. 2018

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Lastly, the company’s quality offices personnel often face difficulties integrating the requirements of the AIFA document with the company’s procedures, as these are often based on UNI EN ISO 9001:2015 standards, while the AIFA document is based on Good Clinical Practice. Therefore, it is necessary to have a significant understanding of the international standards to efficiently integrate them and to create a harmonized Quality Management System that can fit both clinical practice and clinical trial management, as it has been recognized in other research fields [ 22 , 23 , 24 , 25 ].…”

Section: Challenges and Opportunities Of The Clinical Trial Quality Teammentioning

confidence: 99%

The Requirements of Managing Phase I Clinical Trials Risks: The British and Italian Case Studies

Di Tonno,

Martena,

Taurisano

et al. 2024

Epidemiologia

View full text Add to dashboard Cite

Phase I clinical trials represent a critical point in drug development because the investigational medicinal product is being tested in humans for the first time. For this reason, it is essential to evaluate and identify the Maximum Tolerated Dose (MTD) and the safety of the new compound. To mitigate the possible risks associated with drug administration and treatment, the European Competent Authority issued various guidelines to provide provisions and harmonize risk management processes. In the UK and Italy, particular attention should be paid to the Medicines & Healthcare Products Regulatory Agency (MHRA) phase I accreditation scheme and the specific rules set by the Italian Drug Authority through the AIFA Determination no. 809/2015. Both reference documents are based on the concept of quality risk management while conducting phase I clinical studies. Moreover, the AIFA determination outlines specific requirements for those sites that want to conduct non-profit phase I clinical trials. Indeed, the document reports peculiar activities to the “Clinical Trial Quality Team”, which is a team that should support the clinical site researchers in designing, starting, performing, and closing non-profit phase I studies. In this paper, we provide a general overview of the main European guidelines concerning the management of risks during phase I trials, focusing on the main peculiarities of the schemes and rules set by the MHRA and AIFA.

show abstract

“…The process of cement production is very complex and is associated with the consumption of fossil fuels; thus, reducing the amount of cement in concrete indirectly reduces the emission of pollutants. It has been shown that the replacement of cement with 4% nanoparticles such as silica and iron oxides increases the physical and chemical properties of concrete along with saving of cement consumption [1]. Some researchers have tried to increase the properties of materials used in the construction industry, including cement [2][3][4][5] and concrete [6][7][8][9][10] by the use of nanotechnology.…”

Section: Introductionmentioning

confidence: 99%

Influence of functionalized MWCNT on microstructure and mechanical properties of cement paste

Mousavi

Bahari

2019

Sādhanā

View full text Add to dashboard Cite

Today, studies on nanotechnology applications in the construction industry are looking for a solution to reduce the use of cement and consequently to reduce the emission of pollutants in the environment. In this regard, the effect of different percentages of the functionalized multi-walled carbon nanotubes with carboxylic groups (MWCNT) on the modification of mechanical and microstructural properties of hardened cement paste was investigated. The addition ratios of Portland cement with the same weight of MWCNT-COOHs were 0, 0.025, 0.05, 0.1, and 0.2 weight percent (wt%). Moreover, the mechanical and microstructural properties of the hardened cement paste were investigated by the use of Fourier transform infrared spectroscopy (FTIR), X-ray fluorescence spectroscopy (XRF), X-ray diffraction (XRD), X-powder, scanning electron microscope (SEM) and atomic force microscope (AFM) techniques. The results show that replacement of cement with 0.05 wt% of the functionalized carbon nanotube, as the optimal amount, can be considered both for improving mechanical and microstructural properties.

show abstract

Nanoparticle-based concretes for the restoration of historical and contemporary buildings: a new way for CO2 reduction in architecture

Cited by 12 publications

References 3 publications

Nanoparticle Manufacturing – Heterogeneity through Processes to Products

Nanoparticle Manufacturing – Heterogeneity through Processes to Products

The Requirements of Managing Phase I Clinical Trials Risks: The British and Italian Case Studies

Influence of functionalized MWCNT on microstructure and mechanical properties of cement paste

Contact Info

Product

Resources

About